Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 10/23 10:00:00 pm
122.37 USD   +0.86%
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017–7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 01:31pm CEST

Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017–7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene’s management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company’s web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/19 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9782451)
10/19 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Costs Associated with Exit or D..
10/19 CELGENE CORP /DE/ : Costs Associated with Exit or Disposal Activities (form 8-K)
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19 CELGENE : Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Pro..
10/19 CELGENE : Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Mult..
More news
News from SeekingAlpha
10/23 Mongersen Fails
10/23 CELGENE : Still A Great Pipeline, Despite A Setback
10/23 Ozanimod Even More Important For Celgene Now, But Can It Deliver In MS?
10/23 Catalysts loom for Celgene - Morgan Stanley
10/23 BIOTECH FORUM DAILY DIGEST : Behind UniQure's Massive Rally
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 429 M
Net income 2017 4 475 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 16,80
EV / Sales 2017 7,54x
EV / Sales 2018 6,14x
Capitalization 95 736 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 148 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION5.72%95 736
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223